Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

India has officially approved and launched Mounjaro (tirzepatide), a groundbreaking injectable medication for the treatment of Type 2 diabetes and obesity. Developed by Eli Lilly and Company, the drug ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to find out why LLY stock is a Hold.